Drug discovery and subsequent availability of a new breakthrough therapeutic or 'cure' is a compelling example of societal benefit from research advances. These advances are invariably collaborative, involving the contributions of many scientists to a discovery network in which theory and experiment are built upon. 
Introduction
Data mining of public data sources coupled with network analysis enables the quantitative description of research discoveries that were influential in the development of a breakthrough therapeutic or 'cure'. The set of scientific publications, clinical trials, patents, and regulatory approvals, linked to each other by citation or assignment, that documents the progress of concepts from basic research to a cure has been termed a 'cure network' [1] . Science history studies in general and network approaches have been proposed to enable studies of knowledge diffusion across disciplines, scientific interests, culture, and time [2, 3] . Such studies also (i) provide evidence for the broad collaborative platform of basic and translational research underlying major scientific advances such as cures for diseases [4] support strategic communications that help communicate the societal value of research.
The understanding of a therapeutic network, when coupled with information from clinical use of a therapeutic, also enables a recursive learning of the pathogenesis of the disease it is being used to treat, as has been noted for the burgeoning field of immunotherapeutics [5] .
Williams and colleagues have elegantly demonstrated the feasibility and value of data mining and network analysis using, as case studies, ivacaftor and ipilimumab, approved for the treatment of cystic fibrosis and melanoma respectively (vide supra).
Key assumptions in constructing these networks were that references found in relevant documents are appropriate citations of new knowledge relevant to a given cure and that a further retrospective round of citation discovery will reveal previous influential work. They observed that 'the nature of a cure discovery network is complex and fundamentally collaborative', noting in the case of ivacaftor, that at least 7,067 scientists with 5,666 unique affiliations contributed to ivacaftor-relevant research over a period greater than 100 years. These authors also suggested that thoughtful metrics derived from this concept could inform decision making by funders.
In this study, we document the collaboration networks underlying five FDA-approved therapeutics for cancer. Building upon prior art for single networks we (i) extend single network analysis to map publications and authors across multiple networks Table 1 . Case studies of five anti-cancer agents. Five anti-cancer therapeutics, with FDA approval dates ranging from 2001 to 2014, were selected as case studies. The unique identifier for each therapeutic is an FDA assigned NDA or BLA number. While multiple patents are typically associated with a drug or biological, the single US patent number displayed represents the primary invention that preceded approval of the therapeutic. The publication date for each patent is listed in the last column. (ii) include information on research awards and peer review of grants (iii) include enriched data from a commercially available bibliographic database with disambiguated author identifiers, and (iv) incorporate modified network metrics and data mining methods. We observe collaboration that extends across networks and describe the role of funding and peer review in sustaining a system of layered collaborative activity in scientific discovery. By studying additional cures and research advances, we also proceed towards scaling from single case studies to mapping the entire domain of drug development with the expectation that such knowledge will be beneficial in planning, resource allocation and optimization of drug development research. We present the results of this case study to demonstrate a framework that can be easily modified by other researchers to generate new datasets or to complement existing ones.
Materials and methods
Five anti-cancer therapeutics, three drugs and two biologicals, approved for use in humans by the Food and Drug Administration were selected for this study (Table 1) . Imatinib [6] and Sunitinib [7] are tyrosine kinase inhibitors, Nelarabine [8] is a nucleoside analog, and Ramucirumab [9] and Alemtuzumab (Campath) [10] are humanized antibodies that target the CD52 and vEGFR-2 cell surface receptors respectively. For each of these therapeutics, a set of relevant scientific publications was constructed as in Williams et al. [1] but with specific modifications detailed below.
Clinical trials. The national clinical trials database (clinicaltrials.gov) was searched for clinical trials of the five therapeutics that completed by the data of FDA approval by searching for the therapeutic name in the intervention field. Both cited references and publications from these clinical trials were collected if they were published within the approval date plus two months. Patents. Using a combination of web searches, Google Patents, and the scientific literature, a single patent was subjectively identified that best represented the most relevant invention for the therapeutic being considered. Identification of this patent was performed using multiple web sources. The US patent number was then used to identify the patent. For example, US5521184, imatinib, was assigned to the CibaGeigy Corporation in 1996 listing Zimmermann as inventor. The non-patent citation list for a patent was copied from Google Patents [12] and manually processed by searching the PubMed GUI for appropriate pmids using text strings from the citation that, typically, consisted of the last name of the first author, 3-5 words of the title, the year of publication, and journal name. Returned hits were inspected for matches to the original citation in Google Patents and accepted only in the event of a high-degree of confidence in correctness.
Post-approval literature reviews. Review articles published after a therapeutic's approval by the FDA are independent studies of the development of a therapeutic.
Accordingly, PubMed was searched for review articles on these five therapeutics that were published between the date of FDA approval and a year following the date of approval. Cited references in these reviews were extracted using PubMed and Scopus. The review articles themselves were not included. of target records. Accordingly the Scopus data was used as the backbone of the publication component of the network and the cited_pmid information was treated as an annotation layer. These observations are summarized in Table 2 .
Both citing and cited pmids were mapped to NIH grants and peer review panels (study sections) using public information available through NIH ExPORTER [13] .
Thus, we enriched our network data by identifying those study sections associated with the awards that supported publications in our networks.
Networks and network calculations. The resultant data were modeled as networks and analyzed using metrics based on network topology. We calculated the propagated in-degree rank (PIR) and ratio of basic rankings (RBR) metrics of Williams [1] . PIR represents the sum of aggregated citation scores (first and second degree only) for all articles in a network that can be attributed to an author. In addition to computing PIR for all authors in each network, we also combined the citation data for all five networks and computed a network PIR (nPIR) score, which was normalized to the sum of individual PIR scores within each network as the PIR PartitionRatio (PPR) as a way to measure inter-network influence. RBR is intended to represent the fraction of a researcher's output that is in a network and is defined as the ratio of the number of publications in network to the number of publications in a background dataset for an author. In its original specification, the background dataset for RBR was constructed by keyword searches of PubMed. A potential weakness of this keyword based approach is that it does not effectively capture the field or the total output of an author even if multiple background samples are taken. Therefore, we created two new variants of the RBR; network RBR (nRBR) and global-based RBR (gRBR). nRBR uses all publications in our set of five therapeutics as background and gRBR takes advantage of the Scopus author_id to capture the total article output of an author as background. Thus, nRBR and gRBR normalize a researcher's innetwork contributions to backgrounds based on total network and total researcher productivity respectively.
Propagated Indegree Rank (PIR).
In this study, we examine five therapeutics We define network  to be the graph-theoretic union of the networks 1 , 2 , … , 5
(i.e.,  = ∪ ). Thus, the nodes of the network  are the nodes that appear in at least one network , and we include a directed edge between publications and if and only if cites in at least one of the networks ; hence,  is a simple graph (no parallel edges and no self-loops).
Let denote some selected network  , let ( ) be the citation score of publication in , and let  be the set of publications in that cite .
We define the aggregated citation count for within network , denoted by ( ),
Let  be the set of publications for an author in . Then the PIR score for in network is defined by
Next we define the nPIR score of author within network  (denoted by ( ))
to be  ( ); in other words it is the score based on the network  .
We define the PIR partition ratio (PPR) of author (denoted by ( )) to be
There are cases where PPR can be greater than 1.
Ratio of Basic Rankings (RBR).
• nRBR (i.e., network RBR) is the ratio of an author's publication count in a given network to the total publication count for that author in  . Thus, nRBR depends on both the author and the given network , and is denoted by ( , ).
• gRBR, or global RBR, is the ratio of an author's count of publications in network to the author's total publication count in the global network , and is denoted by gRBR( , ).
nRBR( , ) and gRBR( , ) are both ratios with the same numerator but with different denominators, and 0 ≤ nRBR( , ) ≤ gRBR( , ) ≤ 1.
Analysis. All data used in this study were acquired exclusively from the sources listed above. Data used to generate the figures and tables in this study are available in a Mendeley Data repository [14] . Computations were performed on infrastructure owned or leased by NETE Solutions, Elsevier, or the Gladstone Institutes. Code and scripts used in this study were written in Java, Python, and R and are archived on a publicly accessible Github repository [15] . The publicly available codes of the Williams study [16] were used as the basis for designing the codes used in our study. The previous codes were designed to generate graph objects and make use of graph methods such as breadth-first search (BFS) and depth-first search (DFS for graph traversal). In our approach, we used basic data structures like hash maps, hash sets, lists and aggregations and enriched the first generation set of references with data from Scopus, which indexes more scientific journals [17] , cited references from post-approval literature reviews, cited references from FDA Approval Summaries, direct PubMed searches, grants and peer review data. In the Williams study, assembly and analysis of each network took roughly 17 hours per drug, 10 of which are manual processing steps. While our process also involved expert level curation of a foundational set of references for each drug with a cost of roughly 2-5 hours, our network calculations and metrics ran in the order of minutes once the bibliometric data were assembled. Network visualization was performed using Cytoscape [18] .
Results and discussion
Publications. Scientific publications form the backbone of each of these five networks. Our initial assumptions of appropriate citation and retrospective citation discovery (Introduction) suggest that network nodes that are common to multiple networks are likely to be influential. We calculated intersection counts for all possible combinations of publications in the Alemtuzumab, Imatinib, Nelarabine, Ramucirumab, and Sunitinib networks (Table 3) . We also applied intersection analysis at a finer level of granularity by computing intersection counts for both first generation citations (citing_pmid) and second generation citations (cited_sid).
The results are displayed as Venn diagrams in Figure 1 . 14 publications are common to all five networks. Abbreviations: alem (Alemtuzumab), imat (Imatinib), nela (Nelarabine), ramu (Ramucirumab), suni (Sunitinib).
The intersection of all five networks consists of 14 publications out of a total of 106,720 unique Scopus identifiers. Strikingly, not even a single publication is common to all five networks at the first generation level (citing_sid) although a single publication, the pathbreaking work of Kohler and Milstein on the production of monoclonal antibodies [19] , is cited in four out of five networks. All 14 publications are in the second generation of citations (cited_sid) and another 198 comprise the sum of intersections in all possible four-network combinations, roughly an order of magnitude greater than the case of cited references. We manually grouped these 14 publications using high level descriptive terms and observed that this group was composed of statistical methods (5 publications), molecular and cell biological methods (4 publications), analytical and structural biology techniques (3 publications) and cancer biology (2 publications). Of these last two, one is a review of the p53 gene [20] and the second is a study of angiogenesis in children with acute lymphoblastic leukemia [21] . Thus, the majority of this small set of 14 publications describes methods that are heavily cited in these therapeutic development networks, which is consistent with observations of the general scientific literature [22] . Further, they support the concept of basic research contributing to subsequent innovation [23] . The relationship between core publications and their therapeutic networks is visualized in Figure 2 . As the subject of another study, we are actively working on a scalable automated strategy to characterize the entire dataset as well as all combinations of intersections between networks using high level descriptive terms.
Grant support.
With its annual budget of approximately US$32 billion, NIH is a major funder of biomedical research through its granting programs. Understanding the nature and extent of NIH grant support for the research represented in our five networks, provides insight into the funding programs that enabled this research.
We took advantage of publicly available data [13] to identify grant support for the publications in our five networks by mapping them to pmids. A total 19,104 unique grant numbers was harvested of which 112 were found in all five networks.
At the intersection of five networks, the reason the number of grants is larger than the number of publications is because publications and grants exist in a 'many to many' relationship in that each publication can acknowledge support from multiple grants and each grant can support multiple publications. These awards were grouped by major type and visualized ( Figure 3 ). Of note, support from Research Program Projects and Center grants is proportionately larger in the intersection group when compared to the total population where the proportion of research projects is larger. A significant loss of information occurs when mapping from cited_sid to cited_pmid (Table 2 ). Thus we believe that these numbers may be an underestimate of actual grant support from NIH. Also missing from this analysis are details of research support from other funding agencies and industry, which are questions that we intend to pursue. Even so, these data testify to a recurring theme of collaboration and breadth of community engagement also seen at the publication level. We speculate that the broader and collaborative nature of such awards may be more likely to result in a methods-rich population of publications than the more focused research project award but elucidation will require further and more rigorous study.
Peer review.
Research support from NIH is typically made through a two stage peer-review process. The Center for Scientific Review at NIH manages first-stage scientific review of between 50,000-60,000 grant applications each year [24] , a process involving more than 15,000 expert reviewers. In addition, individual Institutes and Centers at NIH manage smaller scale peer review operations. Considering a crude estimate of a 20% success rate in funding, peer review can be viewed as a collaborative scientific activity and that serves as a selection layer for the upper fifth of applications, thus strongly influencing granting outcomes. To describe this layer at a high-level, we matched the awards in the five networks to the peer review panels (study sections) that evaluated them for scientific merit and calculated the intersection and union of these peer review panels. Eighty eight unique panel identifiers formed the intersection. Of these, 11 are distinguishable as Special Emphasis Panels that could be either one-time or recurring panels with temporary members, the remaining 77 are chartered panels with relatively stable membership. Some of these panels are no longer active and public records are not easily available to determine their scientific focus. For the 74 panels that could be classified, beyond an obvious focus on cancer, it is evident that the panels represent a rich mix of disciplines such as chemistry, biophysics, genetics, cell biology, and molecular biology; as well as AIDS, pathology, radiology, endocrinology, neurology, mental health, and child health. Four hundred and seven unique panel identifiers formed the union of all five networks. Of these 28 were Special Emphasis Panels, the remaining 379 panels were chartered as in the case of the intersection. These data provide evidence of broad input from invited experts in a collaborative activity that selects promising scientific projects. Assuming an average of 25 reviewers per panel (the number is likely to range from 5-40) and excluding that some of these panels are likely to have met multiple times during the lifespan of the awards in question and that some of these applications for funding may have been reviewed multiple times, a minimum of 10,000 experts comprised this additional layer of scientific influence. We believe that the actual number is likely to be at least double. A more accurate estimate would be possible if historical records of participation in peer review were made publicly available by NIH. We do not have records of funding awards or peer review conducted by organizations other than NIH and this is a focus of future investigation.
Network metrics. We have built upon the work of Williams [1] by addressing author disambiguation through the use of Scopus authorIDs and enriching the network data with grants and peer review data. Whereas, the original code was designed to handle a single drug and was not applied to a problem larger than 5000 articles, our approach scales to over 100,000 articles and our metrics include cross-network calculations. To quantify network data and to identify influential researchers in and across networks, we calculated PIR and RBR scores for all researchers as well as the new nPIR, PPR, nRBR, and gRBR scores (Materials and Methods). The nPIR metric describes the sum of aggregated citation scores for all articles that a researcher has in all five networks. The PIRpartitionRatio (PPR) normalizes the nPIR metric for an researcher to the sum of the researcher's individual PIR scores for each network being studied. A limitation of the nPIR and nRBR measurements is that they are valid only for the network(s) being studied. Scaling from five to the more than 1400 drugs approved by the FDA (and their many variants) would address this limitation [25] , although other data related issues may well emerge.
While theoretically appealing (Materials and Methods), the gRBR is the most sensitive to data quality since it relies on an accurate estimate of total productivity of a researcher, which in turn depends on data quality in bibliometric databases. We found several instances in the top 10% of PIR scores where the gRBR was implausible likely on account of polysemy, synonymy, or incompleteness. This metric is therefore likely to be useful when article capture and the author disambiguation problem are resolved to the point where data quality is significantly improved and is not recommended except when strong confidence exists in the total productivity counts. These metrics may be best used in conjunction with positional measures such as quantiles to define populations of researchers within related networks, e.g., the top 25 researchers based on nPIR scores of all researchers in our dataset (Table 4 ). These 'bright stars' are elite performers in network(s) of clinical and basic science researchers that reinforce the concept of collaborative translational achievements built upon a body of basic science. Beyond simple aggregation, weighting, and normalization that we have used, a variety of citation metrics such as SNIP [26] , with different normalization strategies at the field, journal, and article level are available for impact analysis and these could be applied to such networks depending on the features of these networks and the aim of the study [27] . The use of these citation measures will assume greater importance with scale up from small numbers of networks to a greater proportion of the global research network.
In this study, we begin with the literature directly cited in the approval process for five therapeutics. The approval process for therapeutics is subject to multiple layers of by which to assess collaboration, productivity, and translational impact. Overall, no single metric will provide very useful answers, instead expert interpretation of multiple metrics best matched to curated datasets will more likely offer value. The method is implicitly time-dependent, allowing one to make historical comparisons and to set future goals. Importantly, our improvements to the method as presented here allow for the analysis across sets of articles in addition to within, supporting higher level interrogations of the crosstalk and collaborations that connect groups.
In summary, we have demonstrated a digital methodology based on data mining and network analysis, not restricted to drug discovery and cures alone, that offers burdenreduction in explorations of science history. The results argue that fundamental research, especially methods, found extensive application in these collaboration networks underlying the development of these five therapeutics. Thus, knowledge from basic research diffused over time to specific applications through the fields of biology, medicine, and pharmaceuticals. Beyond assembling a set of facts about a major scientific advance, the data assembled contribute to the understanding of collaboration across domains and can be used to enrich portfolio analysis, planning and optimization, as well as communications of the societal value of research. For the portfolio manager, such data, when coupled with aggregate measures, enable review on a scale that manual assembly would not permit. For the funder, an understanding of progress towards goals is supported. For the purpose of communication, these data on drug development provide the basis to explain that the work of thousands of scientists working in basic research benefits society since new drugs to combat disease have resulted from publicly supported research. An avenue for further work is application to historiography [30] . The data collected in this approach is largely time-stamped and the 'lag between non-mission research and the eventual innovations' [23] can be studied with respect to the discoveries common to multiple networks. The approach can be adapted to study the collaborative history within and across research portfolios of groups of researchers and targeted programs. While finer critical evaluation of the content of datasets generated through this approach and attempts to optimize resource allocation is best left to experts, the methodology is broadly accessible and can also be viewed as another tool for citizen science.
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